

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 March 2022 (10.03.2022)



(10) International Publication Number
WO 2022/048883 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)

A61K 47/68 (2017.01)

(21) International Application Number:

PCT/EP2021/072595

(22) International Filing Date:

13 August 2021 (13.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20194711.6 04 September 2020 (04.09.2020) EP

20195559.8 10 September 2020 (10.09.2020) EP

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors: **ANDERL, Jan**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **RAAB-WESTPHAL, Sabine**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **HECHT, Stefan**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **DEUTSCH, Carl**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **SHAN, Min**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **KÖNNING, Doreen**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **SLOOT, Willem N.**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **HART, Felix**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **SCHRÖTER, Christian**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **TOLEIKIS, Lars**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **BERGER, Nir**; c/o Interlab Ltd., Hakishon St. No. 18, 8122004 Yavne (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF

(57) Abstract: The invention provides antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.



WO 2022/048883 A1